cd19 car-t cells
Cell therapyexperimental
Clinical trial activity
384 trials · 195 clinical orgs · 0 marketing orgs
Phase 1
291
Phase 2
139
Phase 3
8
Phase 4
2
Earliest trial started Mar 1, 2008 (NCT01493453)
Timeline
Indications
Approved for
Studied for
- Acute Febrile Encephalopathy · Phase 1
- Antigens, CD19 · Phase 1/Phase 2
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 1
- Antiphospholipid Syndrome · Phase 1/Phase 2
- Arthritis, Rheumatoid · Phase 1
- Autoimmune Diseases · Phase 1/Phase 2
- Automobiles · Phase 2
- Blood Transfusion · Phase 1/Phase 2
- Bone Marrow Transplantation · Phase 2
- Burkitt Lymphoma · Phase 3
- Carcinoma, Hepatocellular · Phase 1
- Cell- and Tissue-Based Therapy · Phase 1/Phase 2
- Colorectal Neoplasms · Early Phase 1
- Dermatomyositis · Phase 1/Phase 2
- Drugs, Investigational · Phase 1/Phase 2
- Electroconvulsive Therapy · Phase 1
- Endoscopy · Phase 1
- Glioma · Early Phase 1
- Glomerulonephritis, IGA · Early Phase 1
- Glomerulonephritis, Membranous · Early Phase 1
- Hematologic Neoplasms · Phase 2/Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hodgkin Disease · Phase 2
- Immunotherapy, Adoptive · Phase 2
- Kidney Failure, Chronic · Phase 1
- Kidney Transplantation · Phase 1
- Leukemia · Phase 1/Phase 2
- Leukemia, B-Cell · Phase 2/Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Leukemia, Lymphoid · Phase 2
- Leukemia, Myeloid, Acute · Phase 2/Phase 3
- Leukemia, Prolymphocytic · Phase 1
- Leukemia, Prolymphocytic, B-Cell · Phase 1/Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Lupus Nephritis · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 4
- Lymphoma, Follicular · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Immunoblastic · Phase 2/Phase 3
- Lymphoma, Mantle-Cell · Phase 3
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Early Phase 1
- Multiple Myeloma · Phase 2
- Multiple Sclerosis · Phase 1/Phase 2
- Multiple Sclerosis, Chronic Progressive · Phase 1
- Myasthenia Gravis · Phase 1/Phase 2
- Myositis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuromyelitis Optica · Phase 1
- Only Child · Early Phase 1
- Pancreatic Neoplasms · Phase 1
- Pediatrics · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 1/Phase 2
- POEMS Syndrome · Phase 1
- Polymyositis · Phase 1/Phase 2
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Early Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2/Phase 3
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Purpura, Thrombocytopenic, Idiopathic · Early Phase 1
- Receptors, Chimeric Antigen · Phase 1
- Recurrence · Phase 1/Phase 2
- Renal Insufficiency · Phase 1
- Risk Factors · Phase 2
- Scleroderma, Diffuse · Phase 2
- Scleroderma, Systemic · Phase 1/Phase 2
- Sclerosis · Phase 1/Phase 2
- Sjogren's Syndrome · Phase 1/Phase 2
- Vasculitis · Phase 2
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095147 ↗
Also known as
- acd19z cells
- anti-cd19 car t cells
- anti-cd19 car-t cells
- anti-cd19-car t cells
- anti-cd19-car-t cells
- autologous anti-cd19 car t cells
- autologous car-t
- autologous cd19-targeting car t cells
- car19 t-cells
- car-cd19
- car-cd19 t cells
- car-t
- cart-19
- cart-19 autologous t-cells
- car-t cd19
- cart cd19 cells
- cart cd19 t cells
- cd19 car gene transduced t lymphocytes
- cd19 car t cells
- cd19 car-t cells
- cd19-car-t cells
- cd19cat-41bbz car t-cells
- cd19 gene-modified t cells targeted
- cd19-specific t cell infusion
- hucart19
- im19 car-t
- rna anti-cd19 car t cells
- t cells genetically targeted to the b cell specific antigen cd19
- ucart019
- ucart19
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07261163 | Phase 2 | Dec 20, 2025 | China Academy of Chinese Medical Sciences |
| NCT07275736 | Early Phase 1 (Phase 1) | Dec 15, 2025 | Capital Medical University, Juventas Therapeutics, Inc. |
| NCT07277504 | Early Phase 1 (Phase 1) | Dec 1, 2025 | Government of China, People's Liberation Army of China |
| NCT07233642 | Phase 1 | Nov 30, 2025 | Zhejiang University |
| NCT07252336 | Phase 2 | Nov 30, 2025 | Yake Biotechnology Ltd., Zhejiang University |
| NCT07052305 | Phase 1 | Oct 31, 2025 | NeoImmuneTech, Inc., Washington University in St. Louis |
| NCT07193667 | N/A | Oct 31, 2025 | China Medical University, Government of China |
| NCT07223021 | Phase 3 | Oct 20, 2025 | Memorial Sloan-Kettering Cancer Center, Princess Maxima Center for Pediatric Oncology |
| NCT07212322 | N/A | Oct 10, 2025 | China Academy of Chinese Medical Sciences |
| NCT07198464 | N/A | Oct 7, 2025 | Zhengzhou University |
| NCT07161193 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2025 | Hebei Senlang Biotechnology Inc., Ltd. |
| NCT06850285 | N/A | Sep 5, 2025 | Shanxi Bethune Hospital |
| NCT07152210 | N/A | Sep 1, 2025 | Guangzhou Bio-gene Technology Co., Ltd. |
| NCT07120633 | N/A | Sep 1, 2025 | Xuzhou Medical University |
| NCT07152236 | N/A | Aug 31, 2025 | Guangzhou Bio-gene Technology Co., Ltd. |
| NCT07152223 | N/A | Aug 30, 2025 | Guangzhou Bio-gene Technology Co., Ltd. |
| NCT07143929 | Phase 1 | Aug 18, 2025 | Peking University |
| NCT07137494 | Phase 1 | Aug 14, 2025 | Memorial Sloan-Kettering Cancer Center, Miltenyi Biotec, Inc. |
| NCT07048353 | Early Phase 1 (Phase 1) | Jul 28, 2025 | Hacettepe University, People's Hospital Of Yichang, Qilu Pharmaceutical Co., Ltd., Shanxi Bethune Hospital, Wuhan Central Hospital |
| NCT07072494 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2025 | Southern Medical University |
Showing 20 of 384 trials
Page 1 / 20
Organizations
Research & Development (195)
195 organizations
Page 1 / 10